rusfertide
rusfertide: sourced relationships with 1 company · 2 clinical trials tracked.
rusfertide evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could rusfertide → PTGX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Protagonist Therapeutics, Inc (PTGX) Polycythemia vera (erythrocytosis in patients with PV) | Phase 3 |
Clinical Trial Registry Records (2)
A Phase 2 Open-Label Trial to Evaluate the Efficacy and Safety of the Hepcidin Mimetic Rusfertide (TAK-121) in Chinese Patients With Polycythemia Vera
Primary endpoint: Percentage of Participants Achieving a Response Starting at Week 20 Through Week 32
A Phase 2 Open-label Trial to Evaluate the Efficacy and Safety of Rusfertide in Japanese Patients With Polycythemia Vera
Primary endpoint: Percentage of Participants Achieving a Response Starting at Week 20 through Week 32
Frequently asked questions
Which companies have sourced relationships with rusfertide?
rusfertide has dated SEC/FDA relationship records for Protagonist Therapeutics, Inc.
How many clinical trials involve rusfertide?
BioSniper tracks 2 clinical trials involving rusfertide.